ASI-222
ASI-222 is an aminosugar cardiac glycoside. ASI-222 can inhibit Na+/K+ ATPase and show positive inotropic effect. ASI-222 can be used for the research of cardiovascular disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 59006-00-7
- Fòrmula: C29H45NO7
- Peso molecular:519.67
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 59006-00-7
-
Peso molecular 519.67
-
Fòrmula C29H45NO7
-
SMILES
O[C@@]12[C@@]3([H])[C@@](CC[C@@]1([C@@H](C(CO4)=CC4=O)CC2)C)([H])[C@@]5([C@](C[C@@H](O[C@@]6([H])[C@@H]([C@H]([C@@H](N)[C@@H](C)O6)O)O)CC5)([H])CC3)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)